The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
Mothaffar F. Rimawi
Research Funding - Genentech; GlaxoSmithKline
Christopher John Poole
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
Jean-Marc Ferrero
No relevant relationships to disclose
Juan R. De la Haba Rodriguez
No relevant relationships to disclose
Lada Mitchell
Employment or Leadership Position - Roche
Christina H. Pelizon
Employment or Leadership Position - Roche
Stock Ownership - Roche
Grazia Arpino
Honoraria - GlaxoSmithKline; Roche
Other Remuneration - GlaxoSmithKline; Roche